

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in T-cell engineering for use in... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2344/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2344" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in T-cell engineering for use in immunotherapy" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in T-cell engineering for use in immunotherapy.">
            <meta name="og:description" content="Read the latest article version by Preeti Sharma, David M. Kranz, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9765">
            <meta name="article-id" content="9073">
            <meta name="dc.title" content="Recent advances in T-cell engineering for use in immunotherapy">
            <meta name="dc.description" content="Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs.">
            <meta name="dc.subject" content="immunotherapy, T cell, receptor, neoantigens, chimeric antigen receptor">
            <meta name="dc.creator" content="Sharma, Preeti">
            <meta name="dc.creator" content="Kranz, David M.">
            <meta name="dc.date" content="2016/09/19">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9073.1">
            <meta name="dc.source" content="F1000Research 2016 5:2344">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="immunotherapy ">
            <meta name="prism.keyword" content=" T cell ">
            <meta name="prism.keyword" content=" receptor ">
            <meta name="prism.keyword" content=" neoantigens ">
            <meta name="prism.keyword" content=" chimeric antigen receptor">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/09/19">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2344">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9073.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2344">
            <meta name="citation_title" content="Recent advances in T-cell engineering for use in immunotherapy">
            <meta name="citation_abstract" content="Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs.">
            <meta name="citation_description" content="Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs.">
            <meta name="citation_keywords" content="immunotherapy, T cell, receptor, neoantigens, chimeric antigen receptor">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Preeti Sharma">
            <meta name="citation_author_institution" content="Department of Biochemistry, University of Illinois, Urbana, IL, USA">
            <meta name="citation_author" content="David M. Kranz">
            <meta name="citation_author_institution" content="Department of Biochemistry, University of Illinois, Urbana, IL, USA">
            <meta name="citation_publication_date" content="2016/09/19">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2344">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9073.1">
            <meta name="citation_firstpage" content="2344">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2344/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2344.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9765 /> <input type=hidden id=articleId name=articleId value=9073 /> <input type=hidden id=xmlUrl value="/articles/5-2344/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2344-v1.xml"> <input type=hidden id=article_uuid value=cca9d847-dcc6-4cd0-98f3-ec15eb330dbe /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in T-cell engineering for use in immunotherapy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9073.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9073.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2344"
  },
  "headline": "Recent advances in T-cell engineering for use in immunotherapy",
  "datePublished": "2016-09-19T13:58:26",
  "dateModified": "2016-09-19T13:58:26",
  "author": [
    {
      "@type": "Person",
      "name": "Preeti Sharma"
    },    {
      "@type": "Person",
      "name": "David M. Kranz"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2344",
            "name": "Recent advances in T-cell engineering for use in immunotherapy"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in T-cell engineering for use in immunotherapy </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9765 data-id=9073 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9073.1" data-recommended="" data-doi="10.12688/f1000research.9073.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2344/v1/pdf?article_uuid=cca9d847-dcc6-4cd0-98f3-ec15eb330dbe" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9073-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9073-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9073-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Sharma P and Kranz DM. Recent advances in T-cell engineering for use in immunotherapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2344 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9073.1" target=_blank>https://doi.org/10.12688/f1000research.9073.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9073-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9073 id=track-article-signin-9073 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9073?target=/articles/5-2344">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9765 /> <input name=articleId type=hidden value=9073 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in T-cell engineering for use in immunotherapy</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Preeti Sharma,&nbsp;</span><span class=""><a href="mailto:d-kranz@illinois.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David M. Kranz</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Preeti Sharma,&nbsp;</span><span class=""><a href="mailto:d-kranz@illinois.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David M. Kranz</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 19 Sep 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9073.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Biochemistry, University of Illinois, Urbana, IL, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16415-15471></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16413-15469></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16411-15470></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of <i>ex vivo </i>engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> immunotherapy, T cell, receptor, neoantigens, chimeric antigen receptor </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> David M. Kranz (<a href="mailto:d-kranz@illinois.edu">d-kranz@illinois.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> David M. Kranz </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by current National Institutes of Health grants CA178844 and CA187592. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2016 Sharma P and Kranz DM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Sharma P and Kranz DM. Recent advances in T-cell engineering for use in immunotherapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2344 (<a href="https://doi.org/10.12688/f1000research.9073.1" target=_blank>https://doi.org/10.12688/f1000research.9073.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 19 Sep 2016, <b>5</b>(F1000 Faculty Rev):2344 (<a href="https://doi.org/10.12688/f1000research.9073.1" target=_blank>https://doi.org/10.12688/f1000research.9073.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 19 Sep 2016, <b>5</b>(F1000 Faculty Rev):2344 (<a href="https://doi.org/10.12688/f1000research.9073.1" target=_blank>https://doi.org/10.12688/f1000research.9073.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e176>Introduction</h2><p class="" id=d294942e179>T cells recognize antigens as short peptides bound to a protein encoded by the major histocompatibility complex (MHC). The key T-cell molecule involved in binding to the peptide-MHC (pepMHC) is an  heterodimer called the T-cell receptor (TCR)<sup><a href="#ref-1">1</a></sup>. The TCR is part of a cell surface complex with subunits of CD3, which provide the proximal signaling components. In addition, co-receptors CD4 and CD8 are involved in the recognition of class II and class I MHC, respectively. TCRs have evolved to recognize MHC molecules such that during thymic development, only T cells with TCRs that bind to MHC will be exported to the periphery as mature T cells (termed positive selection)<sup><a href="#ref-2">2</a></sup>. T cells with TCRs that bind self-peptide/MHC with too high affinity will be deleted in the thymus (termed negative selection). The TCR affinities that trigger signaling in these processes are very low, and the range that distinguishes positive selection from negative selection or peripheral T-cell activation appears to be relatively narrow and most likely influenced by the strength of the peptide:MHC interaction<sup><a href="#ref-3">3</a><a href="#ref-5">5</a></sup>.</p><p class="" id=d294942e197>The remarkable feature of the system is that despite their low affinities, TCRs mediate peptide-specific reactivity with very low levels of the pepMHC on the antigen-presenting cells (APCs). Thus, a T cell can be triggered with a TCR affinity of 100 M and only a few pepMHC complexes on the surface of the target cell<sup><a href="#ref-5">5</a><a href="#ref-9">9</a></sup>. This exquisite sensitivity allows the recognition of virtually any intracellular foreign peptide that can be bound to an MHC molecule and transported to the surface. Given these properties, the use of TCRs that recognize tumor-antigen peptides has become an important strategy for adoptive T-cell therapies. Clinical efforts to date have focused on shared self-peptides that are from proteins upregulated in some cancers, such as WT1 antigen, differentiation antigens like gp100 and MART-1, and cancer/testis antigens like NY-ESO and MAGE-A3 (for example,<sup><a href="#ref-10">10</a><a href="#ref-16">16</a></sup>). However, a significant challenge in adoptive T-cell therapy with gene-transferred TCRs is competition for pairing with the endogenous TCR chains, leading to lower levels of the tumor-specific TCR or possibly off-target reactivities of mispaired TCRs that lead to graft-versus-host reactions<sup><a href="#ref-17">17</a></sup>. Current strategies to minimize or avoid mispairing include the use of cysteines in exogenous TCR constant domains that promote preferential pairing<sup><a href="#ref-18">18</a><a href="#ref-20">20</a></sup> or gene editing strategies that limit the expression of the endogenous TCR chains<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>.</p><p class="" id=d294942e232>The other strategy for redirecting the activity of T cells has been to create synthetic receptors that use an antibody fragment (single-chain fragments variable, or scFv) fused to a transmembrane region and signaling domains<sup><a href="#ref-23">23</a></sup>. These chimeric antigen receptors (CARs) have allowed T cells to be targeted against cancers in an MHC-independent mechanism. The most clinically studied CARs are those that target B-cell malignancies, in particular CARs against the antigen CD19 (for example,<sup><a href="#ref-24">24</a><a href="#ref-30">30</a></sup>). However, there is intense interest in developing CARs with other specificities, especially those against cell surface antigens expressed on solid tumors (for example, ErbB2, mesothelin, EGFR, and Tn-glycopeptides<sup><a href="#ref-31">31</a><a href="#ref-36">36</a></sup>).</p><p class="" id=d294942e253>Given the clinical progress with TCR- and CAR-mediated therapies, it is not surprising that there have been numerous reviews on these adoptive T-cell approaches (for example,<sup><a href="#ref-37">37</a><a href="#ref-42">42</a></sup>). Reviews have covered many of the properties that might guide the optimal configuration and application of these receptors, including binding affinities, specificity, construct design, signaling domains (CARs), vector delivery systems, recipient T-cell populations, and manufacturing. Arguably, one of the most important elements of each adoptive T-cell therapy strategy is the choice of target, whether it is a pepMHC for TCR therapies or a cell surface antigen for CAR therapies. With this in mind, we focus here on three features of TCR- or CAR-mediated therapies that have received recent attention: (1) dimensions of the TCR/pepMHC versus CAR/antigen complexes at the synapse, (2) target antigen sensitivity and affinity requirements of T cells expressing TCRs and CARs, and (3) mutated cancer peptides (neoantigens) as targets for adoptive T-cell therapies with TCRs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e266>Dimensions of TCR versus CAR interfaces</h2><p class="" id=d294942e269>Whereas the TCR/CD3 complex has evolved to be an exquisitely sensitive recognition and signaling machine, CARs represent synthetic constructs with distinct differences: antigen binding is accomplished with an scFv, membrane insertion is accomplished using the membrane-spanning region of yet another T-cell molecule (for example, CD8), and intracellular signaling components are derived from multiple T-cell molecules, often the CD3 subunit and CD28, 4-1BB, or OX40. This structural organization endows CARs with MHC-independent binding properties of antibodies and unique signaling properties that share some of the features of normal T cells but that differ in both quantitative and mechanistic details (for example,<sup><a href="#ref-37">37</a><a href="#ref-42">42</a></sup>).</p><p class="" id=d294942e279>Although the TCR/CD3 complex fixes the mechanisms involved in TCR-mediated adoptive T-cell approaches, including the maximal surface level of the complex<sup><a href="#ref-43">43</a></sup>, the design of CARs and their inherent mechanisms continue to evolve. First-generation CARs consisted of an scFv linked to the CD3 subunit in order to more closely mimic the natural TCR/CD3 signaling machinery, in principle allowing clustering and cross-linking of multiple receptors in the membrane. Improvements in signaling capacity and T-cell function were achieved in second- and third-generation CARs by adding the signaling domain(s) of CD28, 4-1BB, or OX40 or a combination of these. These domains were designed to incorporate co-stimulatory signaling (signal 2). Hinge/spacer domains in CARs enable stable expression and typically consist of a hinge linked to the C<sub>H2</sub>-C<sub>H3</sub> domains from IgG1 or IgG4<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup> or spacer domains from CD4 or CD8<sup><a href="#ref-46">46</a></sup>. Reports have shown that CAR T cells containing a hinge from IgG1 Fc regions can bind to Fc receptors (FcRs) and activate cells of the innate immune system<sup><a href="#ref-44">44</a>,<a href="#ref-47">47</a></sup>. Differences in potencies of individual CARs have been associated with choice of co-stimulatory domain used in CAR design, spacer length and its modification if any, target epitope density and location, and inter-membrane distance (for example,<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a>,<a href="#ref-47">47</a><a href="#ref-51">51</a></sup>). A study that used the  chain of FcRI receptor as a signaling domain in a CD30-specific CAR also showed that location of the epitope influenced activity, in that a CAR with a spacer region (C<sub>H2</sub>-C<sub>H3</sub> domains) was less efficient in mediating T-cell activation than the same CAR without the spacer<sup><a href="#ref-52">52</a></sup>.</p><p class="" id=d294942e334>Given the differences in extracellular domains and their antigen structures, the dimensions of the conserved TCR:pepMHC interface can differ substantially from a CAR:antigen interface. TCR:pepMHC interaction interfaces have been studied extensively<sup><a href="#ref-1">1</a>,<a href="#ref-53">53</a><a href="#ref-56">56</a></sup> and crystal structures predict that the static inter-membrane distance for a TCR:pepMHC interaction is about 150  (<a href="#f1">Figure 1A</a>). This has been supported by the measurement of inter-membrane distances at TCR:pepMHC interfaces by electron microscopy<sup><a href="#ref-57">57</a></sup>. The issue of dimensions is important because the kinetic segregation model of TCR triggering proposes that the TCR:pepMHC distance has been optimized to include TCR:pepMHC and accessory receptor-ligand combinations at the synapse while excluding larger inhibitory tyrosine phosphatases (CD45 and CD148)<sup><a href="#ref-57">57</a><a href="#ref-60">60</a></sup>. Accordingly, TCR-mediated adoptive T-cell approaches will automatically retain the same evolutionarily optimized dimensions at the interface.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure1.gif"><img alt="fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure1.gif"></a><div class=caption><h3>Figure 1. Dimensions of the interaction interfaces involving conventional  T-cell receptor (TCR) T cells and chimeric antigen receptor (CAR) T cells.</h3><p id=d294942e371>(<b>A</b>) TCRs on the surface of T cells interact with peptide-major histocompatibility complex (pMHC) complexes on the surface of target cells (antigen-presenting cells). This conserved interaction spans approximately 150  of inter-membrane space between the two cell types. TCRs assemble in the membrane of T cells with subunits of CD3 molecules (, , , and ) and CD4 or CD8 (not shown). Proximal, intracellular molecules initiate phosphorylation of CD3 subunits and subsequent signaling pathways. Structure of the Mel5 TCR in complex with MART-1 peptide bound to HLA-A2 is shown (PDB: 3HG1)<sup><a href="#ref-116">116</a></sup>. (<b>B</b>, <b>C</b>) CARs typically contain single-chain variable fragment (scFv) domains (V<sub>H</sub> and V<sub>L</sub>) of an antibody, linked to a hinge or spacer domain, transmembrane domain, and intracellular signaling domains (for example, co-stimulatory domains CD28 or 4-1BB and CD3). CAR interacts with its antigen present on the target cell surface. Owing to potential differences in the size of the antigen and location of the epitope, the interaction interface of CAR-target antigen can be variable. In (<b>B</b>), a representation of a CAR-target antigen interaction interface is shown by aligning the structures of an extracellular domain of the CAR target, ErbB2, in complex with the scFv of an anti-ErbB2 antibody, chA21 (PDB: 3H3B)<sup><a href="#ref-63">63</a></sup>, with the complete extracellular domain of ErbB2 (PDB: 1N8Z)<sup><a href="#ref-64">64</a></sup>. To illustrate the range of possible CAR interactions, in (<b>C</b>) a representation of another CAR-target antigen interaction interface is shown for mesothelin, a membrane glycoprotein present on the cell surface of various cancers, including mesothelioma. Mesothelin was modeled by using the online tool Phyre2<sup><a href="#ref-117">117</a></sup>, followed by alignment with the domain of mesothelin that was crystallized with the Fab fragment of the anti-mesothelin monoclonal antibody MORAb-009<sup><a href="#ref-65">65</a>,<a href="#ref-118">118</a></sup>. Note that although these are depicted as static structures, both protein dynamics and membrane mobility will also impact interface interactions.</p></div></div><p class="" id=d294942e425>In contrast, distances at the CAR-target antigen interface will be highly variable depending on the size and epitope location of the target antigen. Figures 1B and 1C show a representation of two targets, ErbB2 and mesothelin, which are overexpressed in certain forms of cancer and have been used as targets for immune-based therapies, including CARs<sup><a href="#ref-33">33</a>,<a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. Domains of ErbB2 and mesothelin have been crystallized in complex with antibody domains, allowing a schematic comparison of the possible interfaces that might exist when these proteins are targeted by CARs<sup><a href="#ref-63">63</a><a href="#ref-65">65</a></sup>. The ErbB2/scFv (antibody chA21) predicts that the extracellular domain of ErbB2 is about 115  in length, and the Ig-domains of the scFv measure about 35 to 40 . Thus, the static view of this complex indicates an interaction interface of about 150 , similar to the TCR:pepMHC interaction. In contrast, mesothelin has a very different domain structure with potentially shorter distances at the interaction interface. Both the ErbB2 and mesothelin models highlight the view that the location of the scFv epitope and the flexibility of the membrane-bound target antigen will have a direct influence on the dimensions of the interface. Of course, other factors such as the level of expression of the antigen, its inherent membrane mobility, and the affinity of the scFv will all influence the sensitivity of the CAR reactions. For example, the importance of epitope location has been emphasized by Abken and colleagues, who showed that transfer of a membrane-distal epitope to a membrane-proximal location resulted in improved CAR T-cell activation<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d294942e449>Determining the dimensions of CAR-target antigen interfaces is difficult, as often the structures of the extracellular regions of antigens are not known and, even if they are, the flexibility and membrane mobility of these structures cannot be predicted. Nevertheless, studies have indicated that altering the hinge/spacer domain of CAR constructs impacts their potency, supporting the idea that an optimal distance of interaction for CARs exists, as seen with the TCR:pepMHC interface<sup><a href="#ref-45">45</a>,<a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. For example, ROR1-directed CAR constructs were effective with a shortened spacer domain for recognition and killing of ROR1-positive tumors because of the membrane-distal location of the ROR1 epitope<sup><a href="#ref-48">48</a></sup>. It was hypothesized that shortening the spacer may reduce the distance between T cell and target cell, hence allowing exclusion of inhibitory phosphatases (CD45)<sup><a href="#ref-41">41</a></sup>. Accordingly, a membrane-proximal epitope of ROR1 was efficiently recognized by CARs with a longer spacer<sup><a href="#ref-45">45</a></sup>. Similar results have been observed with CD19-directed CARs<sup><a href="#ref-45">45</a></sup>. As the size of the CAR:antigen dimension was increased with a CD22-directed CAR, the efficiency of target cell lysis was reduced, perhaps because the larger membrane interface permitted CD45-mediated dephosphorylation of substrates involved in T-cell signaling<sup><a href="#ref-49">49</a></sup>. These studies support the importance of maintaining an optimal inter-membrane distance between CAR and target antigen. They suggest that spacer lengths will need to be designed for individual CARs and that scFv fragments against a particular epitope of an antigen may need to be generated.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e486>Target antigen density and affinity requirements for TCRs and CARs</h2><p class="" id=d294942e489>T-cell triggering is not only sensitive to the distance between the antigen-receptor machinery and target cell antigen but also, of course, affected by the density of antigens presented to T cells bearing either the native TCR or the synthetic CAR (<a href="#f2">Figure 2</a>). It has been suggested that one pepMHC molecule may be sufficient to trigger T-cell activation<sup><a href="#ref-6">6</a><a href="#ref-9">9</a></sup>. A factor contributing to this sensitivity, suggested by the serial triggering hypothesis, is that the low affinity (fast off-rate) of the TCR:pepMHC interaction allows serial binding of multiple TCR/CD3 complexes by a single pepMHC complex, thereby amplifying the reaction<sup><a href="#ref-66">66</a></sup>. The extraordinary sensitivity of T cells is also explained by the action of co-receptors CD4 or CD8 which interact with invariant regions of class II or class I MHC and consequently bring the intracellular kinase Lck (lymphocyte specific receptor kinase) into proximity with the TCR/CD3 complex<sup><a href="#ref-67">67</a></sup>. Accordingly, TCR:pepMHC binding drives local aggregation of multiple TCR-pepMHC complexes, leading to Lck-mediated downstream signaling. In the absence of co-receptor, the sensitivity is reduced to about 30 or more pepMHCs, and this co-receptor-independent reaction requires a 10- to 100-fold higher affinity TCR:pepMHC interaction<sup><a href="#ref-3">3</a>,<a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-68">68</a></sup>.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure2.gif"><img alt="fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure2.gif"></a><div class=caption><h3>Figure 2. Sensitivity thresholds for various antibody or T-cell-based therapy modalities.</h3><p id=d294942e533>A comparison of approximated sensitivity thresholds (that is, number of target molecules per cancer cell that are required for killing) that have been identified for antibody or T-cell-based approaches is depicted. Note that these are estimates and that within each category the sensitivity can be further influenced by various parameters, including the affinity of the receptor toward the target antigen. BiTE, bispecific T-cell engager.</p></div></div><p class="" id=d294942e540>Whereas T cells have evolved the machinery to optimize proximal signaling, synthetic CARs have adopted some but not all of these features. In fact, it could be argued that the antigens currently targeted by CARs dictate that the CARs have at least some properties that are different from TCRs. For example, the densities of cell surface antigens recognized by current-generation CARs are orders of magnitude higher than the densities of most specific pepMHC antigens, and these levels vary considerably from one target to another. CAR-based therapies have targeted antigens such as CD19, CD20, and ErbB2 that are expressed at densities that range from 10,000 to 1,000,000 molecules per tumor cell<sup><a href="#ref-36">36</a>,<a href="#ref-62">62</a></sup>. Depending on the system, there may be less information about the minimum number of antigen molecules required by CAR T cells to generate a response. With a unique glycopeptide-directed CAR system, the antigen density required for target cell lysis ranged from 300 to 3,000 epitopes per target cell, and this sensitivity was greater for the scFv used as a CAR compared with its use as a bispecific antibody (also known as BiTEs or bispecific T-cell engagers)<sup><a href="#ref-36">36</a></sup>. More recently, Watanabe and colleagues used a CD20-directed CAR system to establish that the threshold of antigen density required for target cell lysis was about 200 molecules per cell<sup><a href="#ref-69">69</a></sup>. On the other hand, a WT1-human leukocyte antigen (HLA)-A2-directed BiTE system has been shown to induce T-cell response and target-cell killing at 500 to 6,000 epitopes per cell<sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>, whereas current antibody drug conjugates (ADCs) target antigens at significantly higher density (~10<sup>4</sup> to ~10<sup>5</sup>)<sup><a href="#ref-72">72</a></sup>. It is important to note that, whether an antigen is targeted by a CAR, BiTE, or ADC product, each strategy can be optimized within its class to achieve recognition of the lowest antigen levels possible. Ultimately, this depends on the mechanism of action of their respective effector functions. With this in mind, TCRs expressed in T cells are currently the only mediator of activity endowed with the extreme sensitivity to recognize as few as one target molecule per tumor cell (<a href="#f2">Figure 2</a>).</p><p class="" id=d294942e579>Mechanistically, it is not clear whether CARs require the same extent of clustering as TCRs in the T-cell membrane and whether the signaling domains of CARs are actually generating the same stoichiometry and quantitative signaling amplification. The structural organization of CARs allows MHC-independent recognition of antigens, and hence there is no known contribution of co-receptors for further improvements in the sensitivity of this interaction. Accordingly, for each CAR system, it will be important to determine the range of target antigen densities toward which responses against tumor (but not normal tissue) are achieved. This might also require comparison of multiple scFv and CAR formats.</p><p class="" id=d294942e583>Naturally occurring TCRs possess low affinity toward their pepMHC ligands (dissociation constant [K<sub>D</sub>] ranging from 10 to 100 M for foreign pepMHC) but still efficiently induce T-cell activation because of the contribution from co-receptors, serial triggering, and the stoichiometry of the CD3 complex. However, the affinity can be significantly lower for a self-cancer antigen (K<sub>D</sub> of as low as about 1,000 M)<sup><a href="#ref-73">73</a></sup>. Efforts to engineer TCRs for higher affinity are focused on two goals: first, to optimize the activity of CD8 T cells against self-pepMHC (class I) since the higher-affinity TCRs have been deleted during thymic selection<sup><a href="#ref-73">73</a></sup> and, second, to redirect the activity of CD4 T helper cells against a class I MHC target since this interaction would not be able to use the cognate co-receptor CD8<sup><a href="#ref-74">74</a>,<a href="#ref-75">75</a></sup>. Various studies have shown that there is an affinity threshold for TCRs in CD8 T cells (about 10 M) and CD4 T cells (about 1 M) beyond which they risk mediating self-peptide cross-reactivity<sup><a href="#ref-76">76</a><a href="#ref-82">82</a></sup>. Such affinity-enhanced TCRs (for example, against HLA-A1 restricted MAGE-A3 epitope) have been shown to cause off-target cross-reactivity resulting in lethality<sup><a href="#ref-16">16</a>,<a href="#ref-83">83</a>,<a href="#ref-84">84</a></sup>. It is generally accepted that there is no need to engineer TCR affinities below these optimal K<sub>D</sub> values, but again each TCR requires individual testing to assess safety issues.</p><p class="" id=d294942e628>In contrast to TCRs, CARs typically contain scFv fragments from higher-affinity, monoclonal antibodies (K<sub>D</sub> values in the range of 1 to 100 nM). It should be possible to select scFv affinities and CAR formats that avoid stimulation by normal tissues caused by on-target, off-tumor reactions, as apparently was observed with an ErbB2-directed CAR that was reactive with ErbB2 levels in the lungs of a patient<sup><a href="#ref-62">62</a></sup>. A recent study demonstrated the usefulness of low-affinity CAR T cells for distinguishing between malignant and normal cells (high antigen density versus low antigen density), but the high-affinity CAR T cells demonstrated a response that was independent of antigen density, indicating that, as with TCRs, understanding the affinity threshold window is important for controlling responses mediated by CARs<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d294942e642>To directly compare TCRs and CARs, our lab used the recognition domains (V and V) of a high-affinity TCR, formatted either as a conventional full-length  TCR or as a CAR. Although both formats exhibited the same high affinity (30 nM), the TCR format was significantly more sensitive to pepMHC than the CAR format<sup><a href="#ref-86">86</a></sup>, showing that the native TCR/CD3 architecture has evolved more sensitivity than the current CAR designs. In another study, a TCR with a K<sub>D</sub> value of about 1 M was compared with CAR constructs (scFv) with K<sub>D</sub> values of 30 or 400 nM against the same pepMHC<sup><a href="#ref-87">87</a></sup>. The lower-affinity TCR exhibited more potent cytotoxic activity and a high degree of specificity, whereas the high-affinity CAR exhibited reduced cytotoxic activity and loss of specificity.</p><p class="" id=d294942e659>There are various possible explanations for reduced sensitivity of CARs compared with conventional TCRs. The TCR/CD3 assembly in the membrane provides a total of 10 immunoreceptor tyrosine-rich activation motifs (ITAMs) that can be phosphorylated during TCR-pepMHC binding, initiating downstream signaling for T-cell activation<sup><a href="#ref-42">42</a></sup>. Current-generation CARs, on the other hand, contain fewer ITAMs (for example, three) which may yield a reduced level or kinetics (or both) of proximal signaling and corresponding lower sensitivities than TCRs, even when the TCR and CAR have identical binding affinities<sup><a href="#ref-86">86</a></sup>. The co-receptors CD4 or CD8 also participate in the binding and proximal signaling upon TCR interaction with pepMHC, whereas CAR-target antigen interactions do not appear to involve CD4 or CD8. Finally, normal TCR:pepMHC interactions can involve co-stimulatory receptors like CD28 and 4-1BB, further promoting full T-cell activation. In summary, although CAR design has included domains from important T-cell signaling domains (CD3, CD28, or 4-1BB or a combination of these), the ability of CARs to multimerize in the membrane and to associate with other proximal signaling molecules is likely not as efficient as has evolved with TCR-associated machinery.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e673>Neoantigens as targets for TCR-mediated adoptive T-cell therapies</h2><p class="" id=d294942e676>To date, efforts to treat cancer using TCR gene transfer into adoptive T cells have targeted shared cancer-associated antigens, including cancer/testis antigens<sup><a href="#ref-10">10</a>,<a href="#ref-12">12</a>,<a href="#ref-14">14</a></sup>. Whereas TCR-mediated targeting of NY-ESO has shown significant clinical promise<sup><a href="#ref-12">12</a>,<a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>, targeting of MAGE-A3 by two different TCRs led to lethal off-target reactions<sup><a href="#ref-16">16</a>,<a href="#ref-83">83</a>,<a href="#ref-84">84</a></sup>, and targeting of MART1 has been associated with significant on-target, off-tumor side effects<sup><a href="#ref-11">11</a>,<a href="#ref-88">88</a></sup>. Hence, there has been increasing interest in redirecting the activity of T cells against antigens that are unique to tumors in the form of mutated peptides known as neoantigens<sup><a href="#ref-89">89</a><a href="#ref-91">91</a></sup>. Although these antigens represent potential targets with a high level of antigen specificity, they are also typically unique to individual patients and thus pose significant challenges in the development of such personalized TCR-based therapeutics<sup><a href="#ref-92">92</a></sup>. Also, not all patients will possess T cells that mount a response to neoantigens, and one of the challenges will be to determine which neoantigen(s) are expressed at adequate levels on tumors to serve as targets for T-cell therapies.</p><p class="" id=d294942e728>Neoantigens arise as a consequence of somatic mutations in tumors and hence T cells against them are not subject to the same thymic tolerance mechanisms as self-antigens<sup><a href="#ref-90">90</a>,<a href="#ref-93">93</a></sup>. In fact, it is this property that allows cancer patients treated with checkpoint inhibitors against CTLA-4 and PD-1 to elicit immune responses against such neoantigens<sup><a href="#ref-94">94</a><a href="#ref-96">96</a></sup>. The identification of neoantigens from a patients tumor has been performed by whole exome sequencing, when RNA is available for RNASeq analysis (for example,<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>), followed by <i>in silico</i> screening for mutated peptides using HLA-binding and -processing prediction algorithms<sup><a href="#ref-99">99</a><a href="#ref-106">106</a></sup>. Candidate neoantigens are assessed for their ability to elicit T cells by use of synthetic peptides and autologous APCs<sup><a href="#ref-107">107</a></sup>, single-cell analysis using pep-HLA multimers<sup><a href="#ref-108">108</a></sup>, or expression of peptide cassettes in autologous APCs<sup><a href="#ref-109">109</a></sup>.</p><p class="" id=d294942e775>Although some approaches will use neoantigens in vaccine formulations, the use of neoantigens as targets in therapeutic numbers of T cells may benefit from the isolation of TCR genes from T cells that respond to the specific neoantigens, as has been done recently in a mouse system<sup><a href="#ref-110">110</a></sup>. Success here will depend on multiple factors. It has been shown that even with a significant number of predicted neoantigen epitopes, neoantigen-reactive T cells may be limited in some patients with cancer<sup><a href="#ref-91">91</a>,<a href="#ref-111">111</a></sup>. In a recent study, T cells isolated from healthy individuals were used to raise specific T cells against tumor neoantigens derived from patients<sup><a href="#ref-91">91</a></sup>. These results and others suggest that it will be possible to identify TCRs against specific neoantigens and to eventually use them to increase the number of therapeutic T cells by TCR gene transfer.</p><p class="" id=d294942e793>Neoantigens identified by tumor sequencing and bioinformatic analysis of MHC-binding (and possibly antigen-processing) algorithms are not all equal in terms of theoretical efficacy. It is useful to consider the classes that each neoantigenic peptide may represent. First, some predicted peptide epitopes will not be processed, or presented, at levels adequate to elicit T-cell immune responses. The magnitude of this class of neoantigen will vary depending on the robustness of the prediction algorithms for each HLA allele<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>.</p><p class="" id=d294942e804>A second class of neoantigens will be those peptides that have been identified because they were predicted to have greater binding, than the wild-type peptide, to an HLA allele (for example, peptides with a mutation in a known anchor residue or other residues that point toward MHC) (<a href="#f3">Figure 3A</a>). Such a mutation may increase binding of the peptide to the MHC molecule and hence will impact the number of the neoantigen/HLA complexes on the tumor cell surface (that is, density) compared with the number of the wild-type antigen/HLA complexes. Mechanistically, this outcome (higher pepMHC surface levels) is similar to upregulated cancer-associated self-peptides if one assumes that the mutation does not impact the conformation of the peptide region presented to the T cell. T cells with TCRs against these neoantigens, like TCRs against self-peptide cancer-associated antigens, will in general be of lower affinity as T cells expressing higher-affinity TCRs will have been deleted during thymic selection<sup><a href="#ref-73">73</a></sup>.</p><div class="fig panel clearfix"><a name=f3 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure3.gif"><img alt="fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/9765/fd04391a-c329-4bbf-8fd8-c0f17bce7200_figure3.gif"></a><div class=caption><h3>Figure 3. Neoantigens as targets for T cells: possible effects of single mutations.</h3><p id=d294942e824>(<b>A</b>) A mutation in a major histocompatibility complex (MHC) anchor residue (Ala to Leu; shown in red) is shown. Such a mutation could improve the binding of the peptide to MHC and thereby increase the number of peptide-MHC (pepMHC) complexes on a target cell (antigen-presenting cell). (<b>B</b>) A mutation (Ile to Ala; shown in blue) in a residue that points away from the MHC but is in a position to interact with a T-cell receptor (TCR) is shown. Since the normal repertoire of peripheral T cells has not been tolerized against the mutated peptide, there are likely to be some TCRs that have binding affinities for this pepMHC complex that drive T-cell activity. Alternatively, a combination of effects shown in (<b>A</b>) and (<b>B</b>) might be achieved when the mutated residue impacts affinity for the MHC but also alters the conformation of the exposed peptide which could interact with a TCR. For reference, the MART-1 peptide is shown (PDB: 4QOK) and the specific mutations were either present in a known structure (PDB: 3HG1) or modeled by using PyMol.</p></div></div><p class="" id=d294942e843>A third class of neoantigens consists of those peptides that contain a mutation in a residue that points toward the TCR and hence could impact binding to TCR (<a href="#f3">Figure 3B</a>). In principle, these mutated peptides could serve as optimal targets since they will be more immunogenic; that is, peripheral T cells will perceive these peptides as non-self/foreign since the T cells have not been subjected to thymic negative selection.</p><p class="" id=d294942e849>A fourth class of neoantigens includes peptides that have a mutation in a residue that impacts the interaction both with the TCR and with the MHC. These neoantigens could potentially have the strongest impact since the number of neoantigen/HLA complexes would be higher than the wild-type peptide/HLA (assuming the mutation increased binding to the HLA) and the neoantigen-peptide surface recognized by the TCR would differ from the surface of the wild-type peptide, such that T cells with TCRs exhibiting higher affinity would be available in the periphery. We have shown that the number of positions in a peptide that could impact both MHC and TCR binding varies among different MHC alleles<sup><a href="#ref-114">114</a></sup>. It will be important to examine these issues with single amino acid peptide variants tested in many different HLA alleles. Such detailed analysis of mutations at each residue in peptide antigens should provide a better understanding of the potential potency of neoantigens and help guide the selection of neoantigens for adoptive T-cell therapies. Although we have focused here on neoantigens that exhibit single-site mutations, there is the potential for other classes of neoantigens that derive from more extensive mutation, including insertions, deletions, or even glycosylation aberrancies<sup><a href="#ref-115">115</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e863>Concluding remarks</h2><p class="" id=d294942e866>Recent efforts to engineer T cells against cancer have taken two different approaches. Conventional TCR-mediated therapies take advantage of the well-known specificity and sensitivity of normal T-cell activities. Studies have begun to explore the possibilities of engineering T cells by using TCRs against a patients neoantigens. Many of these represent intracellular antigens that would not be accessible by conventional antibody (or CAR) therapies. The selection of the most efficacious neoantigen(s) as targets should consider the mechanistic impact of the mutation and the selection algorithms used to identify these potential antigens.</p><p class="" id=d294942e869>CAR-mediated approaches have tremendous potential against tumor cell surface antigens but their mechanism of action is less fixed than the TCR because of features that vary among different target antigens and CAR constructs. Thus, it is important to find an appropriate balance between antigen on the one side (antigen surface level, epitope location, and antigen mobility) and CAR structure (CAR surface level, affinity, and signaling domains) on the other.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d294942e876>Abbreviations</h2><p class="" id=d294942e879>ADC, antibody drug conjugate; APC, antigen-presenting cell; BiTE, bispecific T-cell engager; CAR, chimeric antigen receptor; HLA, human leukocyte antigen (refers to human major histocompatibility complex alleles); ITAM, immunoreceptor tyrosine-rich activation motif; K<sub>D</sub>, dissociation constant; Lck, lymphocyte-specific receptor kinase; MHC, major histocompatibility complex; pepMHC, peptide complexed with major histocompatibility complex; scFv, single-chain fragments variable; TCR, T-cell receptor.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d294942e1 class=n-a></a><h2 class=main-title id=d295314>Competing interests</h2><p class=metadata-entry><a name=d294942e90 class=n-a></a><p id=d294942e92> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d294942e1 class=n-a></a><h2 class=main-title id=d295316>Grant information</h2><p>This work was supported by current National Institutes of Health grants CA178844 and CA187592.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d294942e889 class=n-a></a><h2 class=main-title id=d294942e891>Acknowledgments</h2><p class="" id=d294942e894>We thank past and present members of the lab for their contributions over the years.</p></div><div class=back-section><a name=d294942e898 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d295751>References</h2><div class="section ref-list"><a name=d294942e898 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1021449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e905 class=n-a></a>Rudolph MG, Stanfield RL, Wilson IA: How TCRs bind MHCs, peptides, and coreceptors. <i>Annu Rev Immunol.</i> 2006; <b>24</b>: 41966. <a target=xrefwindow id=d294942e913 href="http://www.ncbi.nlm.nih.gov/pubmed/16551255">PubMed Abstract </a> | <a target=xrefwindow id=d294942e916 href="http://dx.doi.org/10.1146/annurev.immunol.23.021704.115658">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1021449">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d294942e929 class=n-a></a>Starr TK, Jameson SC, Hogquist KA: Positive and negative selection of T cells. <i>Annu Rev Immunol.</i> 2003; <b>21</b>: 13976. <a target=xrefwindow id=d294942e937 href="http://www.ncbi.nlm.nih.gov/pubmed/12414722">PubMed Abstract </a> | <a target=xrefwindow id=d294942e940 href="http://dx.doi.org/10.1146/annurev.immunol.21.120601.141107">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d294942e949 class=n-a></a>Stone JD, Chervin AS, Kranz DM: T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. <i>Immunology.</i> 2009; <b>126</b>(2): 16576. <a target=xrefwindow id=d294942e957 href="http://www.ncbi.nlm.nih.gov/pubmed/19125887">PubMed Abstract </a> | <a target=xrefwindow id=d294942e960 href="http://dx.doi.org/10.1111/j.1365-2567.2008.03015.x">Publisher Full Text </a> | <a target=xrefwindow id=d294942e963 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2632691">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d294942e972 class=n-a></a>Ebert PJ, Li QJ, Huppa JB, <i> et al.</i>: Functional development of the T cell receptor for antigen. <i>Prog Mol Biol Transl Sci.</i> 2010; <b>92</b>: 65100. <a target=xrefwindow id=d294942e983 href="http://www.ncbi.nlm.nih.gov/pubmed/20800817">PubMed Abstract </a> | <a target=xrefwindow id=d294942e986 href="http://dx.doi.org/10.1016/S1877-1173(10)92004-8">Publisher Full Text </a> | <a target=xrefwindow id=d294942e990 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4887107">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d294942e999 class=n-a></a>Bowerman NA, Crofts TS, Chlewicki L, <i> et al.</i>: Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. <i>Mol Immunol.</i> 2009; <b>46</b>(15): 30008. <a target=xrefwindow id=d294942e1010 href="http://www.ncbi.nlm.nih.gov/pubmed/19595460">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1013 href="http://dx.doi.org/10.1016/j.molimm.2009.06.012">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2773466">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d294942e1027 class=n-a></a>Sykulev Y, Joo M, Vturina I, <i> et al.</i>: Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. <i>Immunity.</i> 1996; <b>4</b>(6): 56571. <a target=xrefwindow id=d294942e1038 href="http://www.ncbi.nlm.nih.gov/pubmed/8673703">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1041 href="http://dx.doi.org/10.1016/S1074-7613(00)80483-5">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d294942e1050 class=n-a></a>Huang J, Brameshuber M, Zeng X, <i> et al.</i>: A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4<sup>+</sup> T cells. <i>Immunity.</i> 2013; <b>39</b>(5): 84657. <a target=xrefwindow id=d294942e1064 href="http://www.ncbi.nlm.nih.gov/pubmed/24120362">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1068 href="http://dx.doi.org/10.1016/j.immuni.2013.08.036">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3846396">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1006670"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1080 class=n-a></a>Irvine DJ, Purbhoo MA, Krogsgaard M, <i> et al.</i>: Direct observation of ligand recognition by T cells. <i>Nature.</i> 2002; <b>419</b>(6909): 8459. <a target=xrefwindow id=d294942e1091 href="http://www.ncbi.nlm.nih.gov/pubmed/12397360">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1094 href="http://dx.doi.org/10.1038/nature01076">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1006670">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d294942e1107 class=n-a></a>Purbhoo MA, Irvine DJ, Huppa JB, <i> et al.</i>: T cell killing does not require the formation of a stable mature immunological synapse. <i>Nat Immunol.</i> 2004; <b>5</b>(5): 52430. <a target=xrefwindow id=d294942e1118 href="http://www.ncbi.nlm.nih.gov/pubmed/15048111">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1121 href="http://dx.doi.org/10.1038/ni1058">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1040361"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1130 class=n-a></a>Morgan RA, Dudley ME, Wunderlich JR, <i> et al.</i>: Cancer regression in patients after transfer of genetically engineered lymphocytes. <i>Science.</i> 2006; <b>314</b>(5796): 1269. <a target=xrefwindow id=d294942e1141 href="http://www.ncbi.nlm.nih.gov/pubmed/16946036">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1144 href="http://dx.doi.org/10.1126/science.1129003">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2267026">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1040361">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d294942e1161 class=n-a></a>Johnson LA, Morgan RA, Dudley ME, <i> et al.</i>: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. <i>Blood.</i> 2009; <b>114</b>(3): 53546. <a target=xrefwindow id=d294942e1172 href="http://www.ncbi.nlm.nih.gov/pubmed/19451549">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1175 href="http://dx.doi.org/10.1182/blood-2009-03-211714">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1179 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2929689">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d294942e1189 class=n-a></a>Robbins PF, Morgan RA, Feldman SA, <i> et al.</i>: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. <i>J Clin Oncol.</i> 2011; <b>29</b>(7): 91724. <a target=xrefwindow id=d294942e1200 href="http://www.ncbi.nlm.nih.gov/pubmed/21282551">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1203 href="http://dx.doi.org/10.1200/JCO.2010.32.2537">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1207 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3068063">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717999941"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1216 class=n-a></a>Chapuis AG, Ragnarsson GB, Nguyen HN, <i> et al.</i>: Transferred WT1-reactive CD8<sup>+</sup> T cells can mediate antileukemic activity and persist in post-transplant patients. <i>Sci Transl Med.</i> 2013; <b>5</b>(174): 174ra27. <a target=xrefwindow id=d294942e1230 href="http://www.ncbi.nlm.nih.gov/pubmed/23447018">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1234 href="http://dx.doi.org/10.1126/scitranslmed.3004916">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1237 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3678970">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717999941">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d294942e1250 class=n-a></a>Robbins PF, Kassim SH, Tran TL, <i> et al.</i>: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. <i>Clin Cancer Res.</i> 2015; <b>21</b>(5): 101927. <a target=xrefwindow id=d294942e1261 href="http://www.ncbi.nlm.nih.gov/pubmed/25538264">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1264 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2708">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1268 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4361810">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d294942e1277 class=n-a></a>Singh N, Kulikovskaya I, Barrett DM, <i> et al.</i>: T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. <i>Oncoimmunology.</i> 2016; <b>5</b>(1): e1040216. <a target=xrefwindow id=d294942e1288 href="http://www.ncbi.nlm.nih.gov/pubmed/26942053">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1291 href="http://dx.doi.org/10.1080/2162402X.2015.1040216">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1295 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4760344">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d294942e1304 class=n-a></a>Morgan RA, Chinnasamy N, Abate-Daga D, <i> et al.</i>: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. <i>J Immunother.</i> 2013; <b>36</b>(2): 13351. <a target=xrefwindow id=d294942e1315 href="http://www.ncbi.nlm.nih.gov/pubmed/23377668">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1318 href="http://dx.doi.org/10.1097/CJI.0b013e3182829903">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3581823">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/3518957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1331 class=n-a></a>Bendle GM, Linnemann C, Hooijkaas AI, <i> et al.</i>: Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. <i>Nat Med.</i> 2010; <b>16</b>(5): 56570, 1p following 570. <a target=xrefwindow id=d294942e1342 href="http://www.ncbi.nlm.nih.gov/pubmed/20400962">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1345 href="http://dx.doi.org/10.1038/nm.2128">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/3518957">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d294942e1359 class=n-a></a>Boulter JM, Glick M, Todorov PT, <i> et al.</i>: Stable, soluble T-cell receptor molecules for crystallization and therapeutics. <i>Protein Eng.</i> 2003; <b>16</b>(9): 70711. <a target=xrefwindow id=d294942e1370 href="http://www.ncbi.nlm.nih.gov/pubmed/14560057">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1373 href="http://dx.doi.org/10.1093/protein/gzg087">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d294942e1382 class=n-a></a>Kuball J, Dossett ML, Wolfl M, <i> et al.</i>: Facilitating matched pairing and expression of TCR chains introduced into human T cells. <i>Blood.</i> 2007; <b>109</b>(6): 23318. <a target=xrefwindow id=d294942e1393 href="http://www.ncbi.nlm.nih.gov/pubmed/17082316">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1396 href="http://dx.doi.org/10.1182/blood-2006-05-023069">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1400 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1852191">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d294942e1409 class=n-a></a>Voss RH, Willemsen RA, Kuball J, <i> et al.</i>: Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. <i>J Immunol.</i> 2008; <b>180</b>(1): 391401. <a target=xrefwindow id=d294942e1420 href="http://www.ncbi.nlm.nih.gov/pubmed/18097040">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1423 href="http://dx.doi.org/10.4049/jimmunol.180.1.391">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d294942e1432 class=n-a></a>Provasi E, Genovese P, Lombardo A, <i> et al.</i>: Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. <i>Nat Med.</i> 2012; <b>18</b>(5): 80715. <a target=xrefwindow id=d294942e1443 href="http://www.ncbi.nlm.nih.gov/pubmed/22466705">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1446 href="http://dx.doi.org/10.1038/nm.2700">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1450 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019824">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d294942e1459 class=n-a></a>Bunse M, Bendle GM, Linnemann C, <i> et al.</i>: RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. <i>Mol Ther.</i> 2014; <b>22</b>(11): 198391. <a target=xrefwindow id=d294942e1470 href="http://www.ncbi.nlm.nih.gov/pubmed/25048215">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1473 href="http://dx.doi.org/10.1038/mt.2014.142">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1477 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4429734">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d294942e1486 class=n-a></a>Eshhar Z, Waks T, Gross G, <i> et al.</i>: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. <i>Proc Natl Acad Sci USA.</i> 1993; <b>90</b>(2): 7204. <a target=xrefwindow id=d294942e1497 href="http://www.ncbi.nlm.nih.gov/pubmed/8421711">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1500 href="http://dx.doi.org/10.1073/pnas.90.2.720">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/45737">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/722007528"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1514 class=n-a></a>Maude SL, Frey N, Shaw PA, <i> et al.</i>: Chimeric antigen receptor T cells for sustained remissions in leukemia. <i>N Engl J Med.</i> 2014; <b>371</b>(16): 150717. <a target=xrefwindow id=d294942e1525 href="http://www.ncbi.nlm.nih.gov/pubmed/25317870">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1528 href="http://dx.doi.org/10.1056/NEJMoa1407222">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1532 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4267531">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/722007528">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718283045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1545 class=n-a></a>Davila ML, Riviere I, Wang X, <i> et al.</i>: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. <i>Sci Transl Med.</i> 2014; <b>6</b>(224): 224ra25. <a target=xrefwindow id=d294942e1556 href="http://www.ncbi.nlm.nih.gov/pubmed/24553386">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1559 href="http://dx.doi.org/10.1126/scitranslmed.3008226">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4684949">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718283045">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/12661956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1576 class=n-a></a>Porter DL, Levine BL, Kalos M, <i> et al.</i>: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. <i>N Engl J Med.</i> 2011; <b>365</b>(8): 72533. <a target=xrefwindow id=d294942e1587 href="http://www.ncbi.nlm.nih.gov/pubmed/21830940">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1590 href="http://dx.doi.org/10.1056/NEJMoa1103849">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1594 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3387277">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/12661956">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d294942e1607 class=n-a></a>Grupp SA, Kalos M, Barrett D, <i> et al.</i>: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. <i>N Engl J Med.</i> 2013; <b>368</b>(16): 150918. <a target=xrefwindow id=d294942e1618 href="http://www.ncbi.nlm.nih.gov/pubmed/23527958">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1621 href="http://dx.doi.org/10.1056/NEJMoa1215134">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1625 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4058440">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d294942e1634 class=n-a></a>Lee DW, Kochenderfer JN, Stetler-Stevenson M, <i> et al.</i>: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet.</i> 2015; <b>385</b>(9967): 51728. <a target=xrefwindow id=d294942e1645 href="http://www.ncbi.nlm.nih.gov/pubmed/25319501">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1648 href="http://dx.doi.org/10.1016/S0140-6736(14)61403-3">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d294942e1657 class=n-a></a>Brudno JN, Somerville RP, Shi V, <i> et al.</i>: Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. <i>J Clin Oncol.</i> 2016; <b>34</b>(10): 111221. <a target=xrefwindow id=d294942e1668 href="http://www.ncbi.nlm.nih.gov/pubmed/26811520">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1671 href="http://dx.doi.org/10.1200/JCO.2015.64.5929">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872017">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d294942e1685 class=n-a></a>Turtle CJ, Hanafi LA, Berger C, <i> et al.</i>: CD19 CAR-T cells of defined CD4<sup>+</sup>:CD8<sup>+</sup> composition in adult B cell ALL patients. <i>J Clin Invest.</i> 2016; <b>126</b>(6): 212338. <a target=xrefwindow id=d294942e1703 href="http://www.ncbi.nlm.nih.gov/pubmed/27111235">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1706 href="http://dx.doi.org/10.1172/JCI85309">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4887159">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d294942e1718 class=n-a></a>Ahmed N, Brawley VS, Hegde M, <i> et al.</i>: Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>J Clin Oncol.</i> 2015; <b>33</b>(15): 168896. <a target=xrefwindow id=d294942e1729 href="http://www.ncbi.nlm.nih.gov/pubmed/25800760">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1732 href="http://dx.doi.org/10.1200/JCO.2014.58.0225">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4429176">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d294942e1745 class=n-a></a>Beatty GL, Haas AR, Maus MV, <i> et al.</i>: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(2): 11220. <a target=xrefwindow id=d294942e1756 href="http://www.ncbi.nlm.nih.gov/pubmed/24579088">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1759 href="http://dx.doi.org/10.1158/2326-6066.CIR-13-0170">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3932715">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d294942e1772 class=n-a></a>Lanitis E, Poussin M, Hagemann IS, <i> et al.</i>: Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. <i>Mol Ther.</i> 2012; <b>20</b>(3): 63343. <a target=xrefwindow id=d294942e1783 href="http://www.ncbi.nlm.nih.gov/pubmed/22127019">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1786 href="http://dx.doi.org/10.1038/mt.2011.256">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1790 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3293635">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725228140"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e1799 class=n-a></a>Adusumilli PS, Cherkassky L, Villena-Vargas J, <i> et al.</i>: Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. <i>Sci Transl Med.</i> 2014; <b>6</b>(261): 261ra151. <a target=xrefwindow id=d294942e1810 href="http://www.ncbi.nlm.nih.gov/pubmed/25378643">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1813 href="http://dx.doi.org/10.1126/scitranslmed.3010162">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4373413">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725228140">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d294942e1830 class=n-a></a>Bullain SS, Sahin A, Szentirmai O, <i> et al.</i>: Genetically engineered T cells to target EGFRvIII expressing glioblastoma. <i>J Neurooncol.</i> 2009; <b>94</b>(3): 37382. <a target=xrefwindow id=d294942e1841 href="http://www.ncbi.nlm.nih.gov/pubmed/19387557">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1844 href="http://dx.doi.org/10.1007/s11060-009-9889-1">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1848 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2730985">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d294942e1858 class=n-a></a>Stone JD, Aggen DH, Schietinger A, <i> et al.</i>: A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). <i>Oncoimmunology.</i> 2012; <b>1</b>(6): 86373. <a target=xrefwindow id=d294942e1869 href="http://www.ncbi.nlm.nih.gov/pubmed/23162754">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1872 href="http://dx.doi.org/10.4161/onci.20592">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3489742">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d294942e1885 class=n-a></a>June CH, Riddell SR, Schumacher TN: Adoptive cellular therapy: a race to the finish line. <i>Sci Transl Med.</i> 2015; <b>7</b>(280): 280ps7. <a target=xrefwindow id=d294942e1893 href="http://www.ncbi.nlm.nih.gov/pubmed/25810311">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1896 href="http://dx.doi.org/10.1126/scitranslmed.aaa3643">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d294942e1905 class=n-a></a>Curran KJ, Brentjens RJ: Chimeric antigen receptor T cells for cancer immunotherapy. <i>J Clin Oncol.</i> 2015; <b>33</b>(15): 17036. <a target=xrefwindow id=d294942e1913 href="http://www.ncbi.nlm.nih.gov/pubmed/25897155">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1916 href="http://dx.doi.org/10.1200/JCO.2014.60.3449">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d294942e1925 class=n-a></a>Jensen MC, Riddell SR: Designing chimeric antigen receptors to effectively and safely target tumors. <i>Curr Opin Immunol.</i> 2015; <b>33</b>(9): 915. <a target=xrefwindow id=d294942e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/25621840">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1936 href="http://dx.doi.org/10.1016/j.coi.2015.01.002">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1939 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4397136">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d294942e1948 class=n-a></a>van der Stegen SJ, Hamieh M, Sadelain M: The pharmacology of second-generation chimeric antigen receptors. <i>Nat Rev Drug Discov.</i> 2015; <b>14</b>(7): 499509. <a target=xrefwindow id=d294942e1956 href="http://www.ncbi.nlm.nih.gov/pubmed/26129802">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1959 href="http://dx.doi.org/10.1038/nrd4597">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d294942e1968 class=n-a></a>Srivastava S, Riddell SR: Engineering CAR-T cells: Design concepts. <i>Trends Immunol.</i> 2015; <b>36</b>(8): 494502. <a target=xrefwindow id=d294942e1976 href="http://www.ncbi.nlm.nih.gov/pubmed/26169254">PubMed Abstract </a> | <a target=xrefwindow id=d294942e1979 href="http://dx.doi.org/10.1016/j.it.2015.06.004">Publisher Full Text </a> | <a target=xrefwindow id=d294942e1982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4746114">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d294942e1992 class=n-a></a>Harris DT, Kranz DM: Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. <i>Trends Pharmacol Sci.</i> 2016; <b>37</b>(3): 22030. <a target=xrefwindow id=d294942e2000 href="http://www.ncbi.nlm.nih.gov/pubmed/26705086">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2003 href="http://dx.doi.org/10.1016/j.tips.2015.11.004">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2006 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4764454">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d294942e2015 class=n-a></a>Minami Y, Weissman AM, Samelson LE, <i> et al.</i>: Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor. <i>Proc Natl Acad Sci USA.</i> 1987; <b>84</b>(9): 268892. <a target=xrefwindow id=d294942e2026 href="http://www.ncbi.nlm.nih.gov/pubmed/3495001">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2029 href="http://dx.doi.org/10.1073/pnas.84.9.2688">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2033 href="http://www.ncbi.nlm.nih.gov/pmc/articles/304723">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d294942e2042 class=n-a></a>Hombach A, Hombach AA, Abken H: Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. <i>Gene Ther.</i> 2010; <b>17</b>(10): 120613. <a target=xrefwindow id=d294942e2050 href="http://www.ncbi.nlm.nih.gov/pubmed/20555360">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2053 href="http://dx.doi.org/10.1038/gt.2010.91">Publisher Full Text </a>|</span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726730887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2063 class=n-a></a>Hudecek M, Sommermeyer D, Kosasih PL, <i> et al.</i>: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for <i>in vivo</i> antitumor activity. <i>Cancer Immunol Res.</i> 2015; <b>3</b>(2): 12535. <a target=xrefwindow id=d294942e2077 href="http://www.ncbi.nlm.nih.gov/pubmed/25212991">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2081 href="http://dx.doi.org/10.1158/2326-6066.CIR-14-0127">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2084 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4692801">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726730887">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d294942e2097 class=n-a></a>Milone MC, Fish JD, Carpenito C, <i> et al.</i>: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy <i>in vivo</i>. <i>Mol Ther.</i> 2009; <b>17</b>(8): 145364. <a target=xrefwindow id=d294942e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/19384291">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2115 href="http://dx.doi.org/10.1038/mt.2009.83">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2118 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2805264">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725351360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2127 class=n-a></a>Almasbak H, Walseng E, Kristian A, <i> et al.</i>: Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. <i>Gene Ther.</i> 2015; <b>22</b>(5): 391403. <a target=xrefwindow id=d294942e2138 href="http://www.ncbi.nlm.nih.gov/pubmed/25652098">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2141 href="http://dx.doi.org/10.1038/gt.2015.4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725351360">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d294942e2155 class=n-a></a>Hudecek M, Lupo-Stanghellini M, Kosasih PL, <i> et al.</i>: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. <i>Clin Cancer Res.</i> 2013; <b>19</b>(12): 315364. <a target=xrefwindow id=d294942e2166 href="http://www.ncbi.nlm.nih.gov/pubmed/23620405">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2169 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0330">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3804130">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d294942e2182 class=n-a></a>James SE, Greenberg PD, Jensen MC, <i> et al.</i>: Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. <i>J Immunol.</i> 2008; <b>180</b>(10): 702838. <a target=xrefwindow id=d294942e2193 href="http://www.ncbi.nlm.nih.gov/pubmed/18453625">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2196 href="http://dx.doi.org/10.4049/jimmunol.180.10.7028">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2200 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2585549">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d294942e2209 class=n-a></a>Guest RD, Hawkins RE, Kirillova N, <i> et al.</i>: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. <i>J Immunother.</i> 2005; <b>28</b>(3): 20311. <a target=xrefwindow id=d294942e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/15838376">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2223 href="http://dx.doi.org/10.1097/01.cji.0000161397.96582.59">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d294942e2232 class=n-a></a>Hombach AA, Schildgen V, Heuser C, <i> et al.</i>: T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. <i>J Immunol.</i> 2007; <b>178</b>(7): 46507. <a target=xrefwindow id=d294942e2243 href="http://www.ncbi.nlm.nih.gov/pubmed/17372024">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2246 href="http://dx.doi.org/10.4049/jimmunol.178.7.4650">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d294942e2255 class=n-a></a>Hombach A, Heuser C, Gerken M, <i> et al.</i>: T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. <i>Gene Ther.</i> 2000; <b>7</b>(12): 106775. <a target=xrefwindow id=d294942e2266 href="http://www.ncbi.nlm.nih.gov/pubmed/10871757">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2269 href="http://dx.doi.org/10.1038/sj.gt.3301195">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d294942e2278 class=n-a></a>Garboczi DN, Ghosh P, Utz U, <i> et al.</i>: Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. <i>Nature.</i> 1996; <b>384</b>(6605): 13441. <a target=xrefwindow id=d294942e2289 href="http://www.ncbi.nlm.nih.gov/pubmed/8906788">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2292 href="http://dx.doi.org/10.1038/384134a0">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d294942e2302 class=n-a></a>Garcia KC, Degano M, Stanfield RL, <i> et al.</i>: An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. <i>Science.</i> 1996; <b>274</b>(5285): 20919. <a target=xrefwindow id=d294942e2313 href="http://www.ncbi.nlm.nih.gov/pubmed/8824178">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2316 href="http://dx.doi.org/10.1126/science.274.5285.209">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d294942e2325 class=n-a></a>Wucherpfennig KW: The first structures of T cell receptors bound to peptide-MHC. <i>J Immunol.</i> 2010; <b>185</b>(11): 63913. <a target=xrefwindow id=d294942e2333 href="http://www.ncbi.nlm.nih.gov/pubmed/21084667">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2336 href="http://dx.doi.org/10.4049/jimmunol.1090110">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d294942e2345 class=n-a></a>Birnbaum ME, Berry R, Hsiao YS, <i> et al.</i>: Molecular architecture of the  T cell receptor-CD3 complex. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(49): 1757681. <a target=xrefwindow id=d294942e2356 href="http://www.ncbi.nlm.nih.gov/pubmed/25422432">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2359 href="http://dx.doi.org/10.1073/pnas.1420936111">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2363 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4267357">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1004858"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2372 class=n-a></a>Choudhuri K, Wiseman D, Brown MH, <i> et al.</i>: T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. <i>Nature.</i> 2005; <b>436</b>(7050): 57882. <a target=xrefwindow id=d294942e2383 href="http://www.ncbi.nlm.nih.gov/pubmed/16049493">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2386 href="http://dx.doi.org/10.1038/nature03843">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1004858">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d294942e2399 class=n-a></a>Davis MM, Krogsgaard M, Huppa JB, <i> et al.</i>: Dynamics of cell surface molecules during T cell recognition. <i>Annu Rev Biochem.</i> 2003; <b>72</b>: 71742. <a target=xrefwindow id=d294942e2410 href="http://www.ncbi.nlm.nih.gov/pubmed/14527326">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2413 href="http://dx.doi.org/10.1146/annurev.biochem.72.121801.161625">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d294942e2422 class=n-a></a>Chakraborty AK, Weiss A: Insights into the initiation of TCR signaling. <i>Nat Immunol.</i> 2014; <b>15</b>(9): 798807. <a target=xrefwindow id=d294942e2430 href="http://www.ncbi.nlm.nih.gov/pubmed/25137454">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2433 href="http://dx.doi.org/10.1038/ni.2940">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726228357"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2443 class=n-a></a>Chang VT, Fernandes RA, Ganzinger KA, <i> et al.</i>: Initiation of T cell signaling by CD45 segregation at 'close contacts'. <i>Nat Immunol.</i> 2016; <b>17</b>(5): 57482. <a target=xrefwindow id=d294942e2454 href="http://www.ncbi.nlm.nih.gov/pubmed/26998761">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2457 href="http://dx.doi.org/10.1038/ni.3392">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2461 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4839504">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726228357">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d294942e2474 class=n-a></a>Zhao Y, Wang QJ, Yang S, <i> et al.</i>: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. <i>J Immunol.</i> 2009; <b>183</b>(9): 556374. <a target=xrefwindow id=d294942e2485 href="http://www.ncbi.nlm.nih.gov/pubmed/19843940">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2488 href="http://dx.doi.org/10.4049/jimmunol.0900447">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d294942e2497 class=n-a></a>Morgan RA, Yang JC, Kitano M, <i> et al.</i>: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing <i>ERBB2</i>. <i>Mol Ther.</i> 2010; <b>18</b>(4): 84351. <a target=xrefwindow id=d294942e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/20179677">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2515 href="http://dx.doi.org/10.1038/mt.2010.24">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2862534">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d294942e2527 class=n-a></a>Zhou H, Zha Z, Liu Y, <i> et al.</i>: Structural insights into the down-regulation of overexpressed p185<sup><i>her2/neu</i></sup> protein of transformed cells by the antibody chA21. <i>J Biol Chem.</i> 2011; <b>286</b>(36): 3167683. <a target=xrefwindow id=d294942e2542 href="http://www.ncbi.nlm.nih.gov/pubmed/21680730">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2546 href="http://dx.doi.org/10.1074/jbc.M111.235184">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2549 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3173138">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1010724"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2558 class=n-a></a>Cho HS, Mason K, Ramyar KX, <i> et al.</i>: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. <i>Nature.</i> 2003; <b>421</b>(6924): 75660. <a target=xrefwindow id=d294942e2569 href="http://www.ncbi.nlm.nih.gov/pubmed/12610629">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2572 href="http://dx.doi.org/10.1038/nature01392">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1010724">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d294942e2585 class=n-a></a>Ma J, Tang WK, Esser L, <i> et al.</i>: Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. <i>J Biol Chem.</i> 2012; <b>287</b>(40): 3312331. <a target=xrefwindow id=d294942e2596 href="http://www.ncbi.nlm.nih.gov/pubmed/22787150">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2599 href="http://dx.doi.org/10.1074/jbc.M112.381756">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2603 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3460419">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d294942e2613 class=n-a></a>Valitutti S, Mller S, Cella M, <i> et al.</i>: Serial triggering of many T-cell receptors by a few peptide-MHC complexes. <i>Nature.</i> 1995; <b>375</b>(6527): 14851. <a target=xrefwindow id=d294942e2624 href="http://www.ncbi.nlm.nih.gov/pubmed/7753171">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2627 href="http://dx.doi.org/10.1038/375148a0">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d294942e2636 class=n-a></a>Artyomov MN, Lis M, Devadas S, <i> et al.</i>: CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(39): 1691621. <a target=xrefwindow id=d294942e2647 href="http://www.ncbi.nlm.nih.gov/pubmed/20837541">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2650 href="http://dx.doi.org/10.1073/pnas.1010568107">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2654 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2947881">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1021281"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2663 class=n-a></a>Li QJ, Dinner AR, Qi S, <i> et al.</i>: CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. <i>Nat Immunol.</i> 2004; <b>5</b>(8): 7919. <a target=xrefwindow id=d294942e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/15247914">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2677 href="http://dx.doi.org/10.1038/ni1095">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1021281">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725282479"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2690 class=n-a></a>Watanabe K, Terakura S, Martens AC, <i> et al.</i>: Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells. <i>J Immunol.</i> 2015; <b>194</b>(3): 91120. <a target=xrefwindow id=d294942e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/25520398">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2704 href="http://dx.doi.org/10.4049/jimmunol.1402346">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725282479">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d294942e2717 class=n-a></a>Veomett N, Dao T, Liu H, <i> et al.</i>: Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. <i>Clin Cancer Res.</i> 2014; <b>20</b>(15): 403646. <a target=xrefwindow id=d294942e2728 href="http://www.ncbi.nlm.nih.gov/pubmed/24850840">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2731 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-2756">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4119489">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d294942e2744 class=n-a></a>Dao T, Pankov D, Scott A, <i> et al.</i>: Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. <i>Nat Biotechnol.</i> 2015; <b>33</b>(10): 107986. <a target=xrefwindow id=d294942e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/26389576">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2758 href="http://dx.doi.org/10.1038/nbt.3349">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4600043">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d294942e2772 class=n-a></a>Perez HL, Cardarelli PM, Deshpande S, <i> et al.</i>: Antibody-drug conjugates: current status and future directions. <i>Drug Discov Today.</i> 2014; <b>19</b>(7): 86981. <a target=xrefwindow id=d294942e2783 href="http://www.ncbi.nlm.nih.gov/pubmed/24239727">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2786 href="http://dx.doi.org/10.1016/j.drudis.2013.11.004">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d294942e2795 class=n-a></a>Aleksic M, Liddy N, Molloy PE, <i> et al.</i>: Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. <i>Eur J Immunol.</i> 2012; <b>42</b>(12): 31749. <a target=xrefwindow id=d294942e2806 href="http://www.ncbi.nlm.nih.gov/pubmed/22949370">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2809 href="http://dx.doi.org/10.1002/eji.201242606">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2813 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3776049">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d294942e2822 class=n-a></a>Engels B, Chervin AS, Sant AJ, <i> et al.</i>: Long-term persistence of CD4<sup>+</sup> but rapid disappearance of CD8<sup>+</sup> T cells expressing an MHC class I-restricted TCR of nanomolar affinity. <i>Mol Ther.</i> 2012; <b>20</b>(3): 65260. <a target=xrefwindow id=d294942e2840 href="http://www.ncbi.nlm.nih.gov/pubmed/22233579">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2843 href="http://dx.doi.org/10.1038/mt.2011.286">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2846 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3293607">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d294942e2855 class=n-a></a>Soto CM, Stone JD, Chervin AS, <i> et al.</i>: MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy <i>in vivo</i> compared to the micromolar wild-type TCR. <i>Cancer Immunol Immunother.</i> 2013; <b>62</b>(2): 35969. <a target=xrefwindow id=d294942e2869 href="http://www.ncbi.nlm.nih.gov/pubmed/22926060">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2873 href="http://dx.doi.org/10.1007/s00262-012-1336-z">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3570684">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d294942e2885 class=n-a></a>Holler PD, Chlewicki LK, Kranz DM: TCRs with high affinity for foreign pMHC show self-reactivity. <i>Nat Immunol.</i> 2003; <b>4</b>(1): 5562. <a target=xrefwindow id=d294942e2893 href="http://www.ncbi.nlm.nih.gov/pubmed/12469116">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2896 href="http://dx.doi.org/10.1038/ni863">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d294942e2905 class=n-a></a>Zhao Y, Bennett AD, Zheng Z, <i> et al.</i>: High-affinity TCRs generated by phage display provide CD4<sup>+</sup> T cells with the ability to recognize and kill tumor cell lines. <i>J Immunol.</i> 2007; <b>179</b>(9): 584554. <a target=xrefwindow id=d294942e2919 href="http://www.ncbi.nlm.nih.gov/pubmed/17947658">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2923 href="http://dx.doi.org/10.4049/jimmunol.179.9.5845">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2926 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2140228">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d294942e2936 class=n-a></a>Chervin AS, Stone JD, Holler PD, <i> et al.</i>: The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. <i>J Immunol.</i> 2009; <b>183</b>(2): 116678. <a target=xrefwindow id=d294942e2947 href="http://www.ncbi.nlm.nih.gov/pubmed/19553539">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2950 href="http://dx.doi.org/10.4049/jimmunol.0900054">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2841305">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d294942e2963 class=n-a></a>Corse E, Gottschalk RA, Krogsgaard M, <i> et al.</i>: Attenuated T cell responses to a high-potency ligand <i>in vivo</i>. <i>PLoS Biol.</i> 2010; <b>8</b>(9): pii: e1000481. <a target=xrefwindow id=d294942e2977 href="http://www.ncbi.nlm.nih.gov/pubmed/20856903">PubMed Abstract </a> | <a target=xrefwindow id=d294942e2981 href="http://dx.doi.org/10.1371/journal.pbio.1000481">Publisher Full Text </a> | <a target=xrefwindow id=d294942e2984 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2939023">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718002772"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e2993 class=n-a></a>Zhong S, Malecek K, Johnson LA, <i> et al.</i>: T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(17): 69738. <a target=xrefwindow id=d294942e3004 href="http://www.ncbi.nlm.nih.gov/pubmed/23576742">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3007 href="http://dx.doi.org/10.1073/pnas.1221609110">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3637771">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718002772">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717977122"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3024 class=n-a></a>Hebeisen M, Baitsch L, Presotto D, <i> et al.</i>: SHP-1 phosphatase activity counteracts increased T cell receptor affinity. <i>J Clin Invest.</i> 2013; <b>123</b>(3): 104456. <a target=xrefwindow id=d294942e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/23391724">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3038 href="http://dx.doi.org/10.1172/JCI65325">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3582132">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717977122">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1147565"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3055 class=n-a></a>Zehn D, Lee SY, Bevan MJ: Complete but curtailed T-cell response to very low-affinity antigen. <i>Nature.</i> 2009; <b>458</b>(7235): 2114. <a target=xrefwindow id=d294942e3063 href="http://www.ncbi.nlm.nih.gov/pubmed/19182777">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3066 href="http://dx.doi.org/10.1038/nature07657">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2735344">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1147565">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d294942e3082 class=n-a></a>Cameron BJ, Gerry AB, Dukes J, <i> et al.</i>: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. <i>Sci Transl Med.</i> 2013; <b>5</b>(197): 197ra103. <a target=xrefwindow id=d294942e3093 href="http://www.ncbi.nlm.nih.gov/pubmed/23926201">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3096 href="http://dx.doi.org/10.1126/scitranslmed.3006034">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d294942e3106 class=n-a></a>Linette GP, Stadtmauer EA, Maus MV, <i> et al.</i>: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. <i>Blood.</i> 2013; <b>122</b>(6): 86371. <a target=xrefwindow id=d294942e3117 href="http://www.ncbi.nlm.nih.gov/pubmed/23770775">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3120 href="http://dx.doi.org/10.1182/blood-2013-03-490565">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3124 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743463">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725765400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3133 class=n-a></a>Caruso HG, Hurton LV, Najjar A, <i> et al.</i>: Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. <i>Cancer Res.</i> 2015; <b>75</b>(17): 350518. <a target=xrefwindow id=d294942e3144 href="http://www.ncbi.nlm.nih.gov/pubmed/26330164">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3147 href="http://dx.doi.org/10.1158/0008-5472.CAN-15-0139">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3151 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4624228">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725765400">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d294942e3164 class=n-a></a>Stone JD, Harris DT, Soto CM, <i> et al.</i>: A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. <i>Cancer Immunol Immunother.</i> 2014; <b>63</b>(11): 116376. <a target=xrefwindow id=d294942e3175 href="http://www.ncbi.nlm.nih.gov/pubmed/25082071">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3178 href="http://dx.doi.org/10.1007/s00262-014-1586-z">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3182 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4262137">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d294942e3191 class=n-a></a>Oren R, Hod-Marco M, Haus-Cohen M, <i> et al.</i>: Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. <i>J Immunol.</i> 2014; <b>193</b>(11): 573343. <a target=xrefwindow id=d294942e3202 href="http://www.ncbi.nlm.nih.gov/pubmed/25362181">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3205 href="http://dx.doi.org/10.4049/jimmunol.1301769">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d294942e3214 class=n-a></a>van den Berg JH, Gomez-Eerland R, van de Wiel B, <i> et al.</i>: Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. <i>Mol Ther.</i> 2015; <b>23</b>(9): 154150. <a target=xrefwindow id=d294942e3225 href="http://www.ncbi.nlm.nih.gov/pubmed/25896248">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3228 href="http://dx.doi.org/10.1038/mt.2015.60">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3232 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4817886">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d294942e3241 class=n-a></a>Blankenstein T, Leisegang M, Uckert W, <i> et al.</i>: Targeting cancer-specific mutations by T cell receptor gene therapy. <i>Curr Opin Immunol.</i> 2015; <b>33</b>: 1129. <a target=xrefwindow id=d294942e3252 href="http://www.ncbi.nlm.nih.gov/pubmed/25728991">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3255 href="http://dx.doi.org/10.1016/j.coi.2015.02.005">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4557613">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d294942e3269 class=n-a></a>Schumacher TN, Schreiber RD: Neoantigens in cancer immunotherapy. <i>Science.</i> 2015; <b>348</b>(6230): 6974. <a target=xrefwindow id=d294942e3277 href="http://www.ncbi.nlm.nih.gov/pubmed/25838375">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3280 href="http://dx.doi.org/10.1126/science.aaa4971">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726369602"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3289 class=n-a></a>Strnen E, Toebes M, Kelderman S, <i> et al.</i>: Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. <i>Science.</i> 2016; <b>352</b>(6291): 133741. <a target=xrefwindow id=d294942e3300 href="http://www.ncbi.nlm.nih.gov/pubmed/27198675">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3303 href="http://dx.doi.org/10.1126/science.aaf2288">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726369602">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d294942e3316 class=n-a></a>Gubin MM, Artyomov MN, Mardis ER, <i> et al.</i>: Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>J Clin Invest.</i> 2015; <b>125</b>(9): 341321. <a target=xrefwindow id=d294942e3327 href="http://www.ncbi.nlm.nih.gov/pubmed/26258412">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3330 href="http://dx.doi.org/10.1172/JCI80008">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3334 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4588307">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d294942e3343 class=n-a></a>Ward JP, Gubin MM, Schreiber RD: The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Adv Immunol.</i> 2016; <b>130</b>: 2574. <a target=xrefwindow id=d294942e3351 href="http://www.ncbi.nlm.nih.gov/pubmed/26922999">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3354 href="http://dx.doi.org/10.1016/bs.ai.2016.01.001">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725241175"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3363 class=n-a></a>Snyder A, Makarov V, Merghoub T, <i> et al.</i>: Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>N Engl J Med.</i> 2014; <b>371</b>(23): 218999. <a target=xrefwindow id=d294942e3374 href="http://www.ncbi.nlm.nih.gov/pubmed/25409260">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3377 href="http://dx.doi.org/10.1056/NEJMoa1406498">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4315319">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725241175">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725249072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3394 class=n-a></a>Gubin MM, Zhang X, Schuster H, <i> et al.</i>: Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature.</i> 2014; <b>515</b>(7528): 57781. <a target=xrefwindow id=d294942e3405 href="http://www.ncbi.nlm.nih.gov/pubmed/25428507">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3408 href="http://dx.doi.org/10.1038/nature13988">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3412 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4279952">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725249072">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725388762"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3426 class=n-a></a>Rizvi NA, Hellmann MD, Snyder A, <i> et al.</i>: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science.</i> 2015; <b>348</b>(6230): 1248. <a target=xrefwindow id=d294942e3437 href="http://www.ncbi.nlm.nih.gov/pubmed/25765070">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3440 href="http://dx.doi.org/10.1126/science.aaa1348">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3444 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4993154">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725388762">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d294942e3457 class=n-a></a>Robbins PF, Lu YC, El-Gamil M, <i> et al.</i>: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. <i>Nat Med.</i> 2013; <b>19</b>(6): 74752. <a target=xrefwindow id=d294942e3468 href="http://www.ncbi.nlm.nih.gov/pubmed/23644516">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3471 href="http://dx.doi.org/10.1038/nm.3161">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3475 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3757932">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d294942e3484 class=n-a></a>Kalaora S, Barnea E, Merhavi-Shoham E, <i> et al.</i>: Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. <i>Oncotarget.</i> 2016; <b>7</b>(5): 51107. <a target=xrefwindow id=d294942e3495 href="http://www.ncbi.nlm.nih.gov/pubmed/26819371">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3498 href="http://dx.doi.org/10.18632/oncotarget.6960">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3502 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4868674">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d294942e3511 class=n-a></a>Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. <i>J Immunol.</i> 1994; <b>152</b>(1): 16375. <a target=xrefwindow id=d294942e3519 href="http://www.ncbi.nlm.nih.gov/pubmed/8254189">PubMed Abstract </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d294942e3528 class=n-a></a>Rammensee H, Bachmann J, Emmerich NP, <i> et al.</i>: SYFPEITHI: database for MHC ligands and peptide motifs. <i>Immunogenetics.</i> 1999; <b>50</b>(34): 2139. <a target=xrefwindow id=d294942e3539 href="http://www.ncbi.nlm.nih.gov/pubmed/10602881">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3542 href="http://dx.doi.org/10.1007/s002510050595">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d294942e3551 class=n-a></a>Nielsen M, Lundegaard C, Worning P, <i> et al.</i>: Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. <i>Protein Sci.</i> 2003; <b>12</b>(5): 100717. <a target=xrefwindow id=d294942e3562 href="http://www.ncbi.nlm.nih.gov/pubmed/12717023">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3565 href="http://dx.doi.org/10.1110/ps.0239403">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3569 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2323871">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d294942e3579 class=n-a></a>Peters B, Sette A: Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. <i>BMC Bioinformatics.</i> 2005; <b>6</b>: 132. <a target=xrefwindow id=d294942e3587 href="http://www.ncbi.nlm.nih.gov/pubmed/15927070">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3590 href="http://dx.doi.org/10.1186/1471-2105-6-132">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1173087">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d294942e3602 class=n-a></a>Nielsen M, Lundegaard C, Blicher T, <i> et al.</i>: <i>NetMHCpan</i>, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. <i>PLoS One.</i> 2007; <b>2</b>(8): e796. <a target=xrefwindow id=d294942e3616 href="http://www.ncbi.nlm.nih.gov/pubmed/17726526">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3620 href="http://dx.doi.org/10.1371/journal.pone.0000796">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1949492">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d294942e3632 class=n-a></a>Fritsch EF, Rajasagi M, Ott PA, <i> et al.</i>: HLA-binding properties of tumor neoepitopes in humans. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(6): 5229. <a target=xrefwindow id=d294942e3643 href="http://www.ncbi.nlm.nih.gov/pubmed/24894089">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3646 href="http://dx.doi.org/10.1158/2326-6066.CIR-13-0227">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4049249">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d294942e3659 class=n-a></a>Berkers CR, de Jong A, Schuurman KG, <i> et al.</i>: Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. <i>J Immunol.</i> 2015; <b>195</b>(9): 408595. <a target=xrefwindow id=d294942e3670 href="http://www.ncbi.nlm.nih.gov/pubmed/26401003">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3673 href="http://dx.doi.org/10.4049/jimmunol.1402455">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3677 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4642839">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d294942e3686 class=n-a></a>Paul S, Dillon MB, Lindestam Arlehamn CS, <i> et al.</i>: A population response analysis approach to assign class II HLA-epitope restrictions. <i>J Immunol.</i> 2015; <b>194</b>(12): 616476. <a target=xrefwindow id=d294942e3697 href="http://www.ncbi.nlm.nih.gov/pubmed/25948811">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3700 href="http://dx.doi.org/10.4049/jimmunol.1403074">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3704 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4458389">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725303475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3713 class=n-a></a>Linnemann C, van Buuren MM, Bies L, <i> et al.</i>: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4<sup>+</sup> T cells in human melanoma. <i>Nat Med.</i> 2015; <b>21</b>(1): 815. <a target=xrefwindow id=d294942e3727 href="http://www.ncbi.nlm.nih.gov/pubmed/25531942">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3731 href="http://dx.doi.org/10.1038/nm.3773">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725303475">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718463163"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3745 class=n-a></a>Han A, Glanville J, Hansmann L, <i> et al.</i>: Linking T-cell receptor sequence to functional phenotype at the single-cell level. <i>Nat Biotechnol.</i> 2014; <b>32</b>(7): 68492. <a target=xrefwindow id=d294942e3756 href="http://www.ncbi.nlm.nih.gov/pubmed/24952902">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3759 href="http://dx.doi.org/10.1038/nbt.2938">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4337815">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718463163">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726166120"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3776 class=n-a></a>Gros A, Parkhurst MR, Tran E, <i> et al.</i>: Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <i>Nat Med.</i> 2016; <b>22</b>(4): 4338. <a target=xrefwindow id=d294942e3787 href="http://www.ncbi.nlm.nih.gov/pubmed/26901407">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3790 href="http://dx.doi.org/10.1038/nm.4051">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726166120">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726014870"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3803 class=n-a></a>Leisegang M, Engels B, Schreiber K, <i> et al.</i>: Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. <i>Clin Cancer Res.</i> 2016; <b>22</b>(11): 273443. <a target=xrefwindow id=d294942e3814 href="http://www.ncbi.nlm.nih.gov/pubmed/26667491">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3817 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-2361">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4891260">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726014870">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d294942e3834 class=n-a></a>van Rooij N, van Buuren MM, Philips D, <i> et al.</i>: Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. <i>J Clin Oncol.</i> 2013; <b>31</b>(32): e43942. <a target=xrefwindow id=d294942e3845 href="http://www.ncbi.nlm.nih.gov/pubmed/24043743">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3848 href="http://dx.doi.org/10.1200/JCO.2012.47.7521">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3852 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3836220">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d294942e3861 class=n-a></a>van Buuren MM, Dijkgraaf FE, Linnemann C, <i> et al.</i>: HLA micropolymorphisms strongly affect peptide-MHC multimer-based monitoring of antigen-specific CD8<sup>+</sup> T cell responses. <i>J Immunol.</i> 2014; <b>192</b>(2): 6418. <a target=xrefwindow id=d294942e3875 href="http://www.ncbi.nlm.nih.gov/pubmed/24342804">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3879 href="http://dx.doi.org/10.4049/jimmunol.1301770">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d294942e3888 class=n-a></a>van Buuren MM, Calis JJ, Schumacher TN: High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. <i>Oncoimmunology.</i> 2014; <b>3</b>(5): e28836. <a target=xrefwindow id=d294942e3896 href="http://www.ncbi.nlm.nih.gov/pubmed/25083320">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3899 href="http://dx.doi.org/10.4161/onci.28836">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3902 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4106163">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d294942e3912 class=n-a></a>Bowerman NA, Colf LA, Garcia KC, <i> et al.</i>: Different strategies adopted by K<sup>b</sup> and L<sup>d</sup> to generate T cell specificity directed against their respective bound peptides. <i>J Biol Chem.</i> 2009; <b>284</b>(47): 3255161. <a target=xrefwindow id=d294942e3930 href="http://www.ncbi.nlm.nih.gov/pubmed/19755422">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3933 href="http://dx.doi.org/10.1074/jbc.M109.040501">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2781669">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1047685"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d294942e3945 class=n-a></a>Schietinger A, Philip M, Yoshida BA, <i> et al.</i>: A mutant chaperone converts a wild-type protein into a tumor-specific antigen. <i>Science.</i> 2006; <b>314</b>(5797): 3048. <a target=xrefwindow id=d294942e3956 href="http://www.ncbi.nlm.nih.gov/pubmed/17038624">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3959 href="http://dx.doi.org/10.1126/science.1129200">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1047685">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d294942e3972 class=n-a></a>Cole DK, Yuan F, Rizkallah PJ, <i> et al.</i>: Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. <i>J Biol Chem.</i> 2009; <b>284</b>(40): 272819. <a target=xrefwindow id=d294942e3983 href="http://www.ncbi.nlm.nih.gov/pubmed/19605354">PubMed Abstract </a> | <a target=xrefwindow id=d294942e3986 href="http://dx.doi.org/10.1074/jbc.M109.022509">Publisher Full Text </a> | <a target=xrefwindow id=d294942e3990 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2785656">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d294942e3999 class=n-a></a>Kelley LA, Mezulis S, Yates CM, <i> et al.</i>: The Phyre2 web portal for protein modeling, prediction and analysis. <i>Nat Protoc.</i> 2015; <b>10</b>(6): 84558. <a target=xrefwindow id=d294942e4010 href="http://www.ncbi.nlm.nih.gov/pubmed/25950237">PubMed Abstract </a> | <a target=xrefwindow id=d294942e4013 href="http://dx.doi.org/10.1038/nprot.2015.053">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d294942e4022 class=n-a></a>Hassan R, Cohen SJ, Phillips M, <i> et al.</i>: Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. <i>Clin Cancer Res.</i> 2010; <b>16</b>(24): 61328. <a target=xrefwindow id=d294942e4033 href="http://www.ncbi.nlm.nih.gov/pubmed/21037025">PubMed Abstract </a> | <a target=xrefwindow id=d294942e4036 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-2275">Publisher Full Text </a> | <a target=xrefwindow id=d294942e4040 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3057907">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2344&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2344&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Biochemistry, University of Illinois, Urbana, IL, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2344/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 19 Sep 2016, 5:2344 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9073.1">https://doi.org/10.12688/f1000research.9073.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2016 Sharma P and Kranz DM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9765 data-id=9073 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9073.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2344/v1/pdf?article_uuid=cca9d847-dcc6-4cd0-98f3-ec15eb330dbe" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9073.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Sharma P and Kranz DM. Recent advances in T-cell engineering for use in immunotherapy [version 1; peer review: 3 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2344 (<a href="https://doi.org/10.12688/f1000research.9073.1" target=_blank>https://doi.org/10.12688/f1000research.9073.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9073 id=mobile-track-article-signin-9073 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9073?target=/articles/5-2344"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9765 /> <input name=articleId type=hidden value=9073 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Stanley Riddell</strong>, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Hinrich Abken</strong>, Center for Molecular Medicine Cologne, University of Cologne; Clinic of Internal Medicine I, University Hospital Cologne, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Michelle Krogsgaard</strong>, Department of Pathology, New York University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2344&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2344&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16415-15471></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16413-15469></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16411-15470></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2344/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>19 Sep 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stanley Riddell</strong>, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Hinrich Abken</strong>, Center for Molecular Medicine Cologne, University of Cologne; Clinic of Internal Medicine I, University Hospital Cologne, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Michelle Krogsgaard</strong>, Department of Pathology, New York University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2344&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2344/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in T-cell engineering for...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2344/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2344/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2344/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Sharma P and Kranz DM');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2344/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2344",
            templates : {
                twitter : "Recent advances in T-cell engineering for use in immunotherapy. Sharma P and Kranz DM, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2344/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in T-cell engineering for use in immunotherapy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in T-cell engineering for use in immunotherapy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9073/9765")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9765");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15469": 0,
                           "15470": 0,
                           "15471": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "7fee0b5d-21e4-49d8-8127-0e708fff558c";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2344.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2344.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2344.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2344.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2344.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>